Targeting a MYC-directed metabolic vulnerability sensitizes tyrosine kinase inhibitor therapy with selectivity
A key strategy for precision therapy lies in identifying and targeting tumor cell-specific metabolic vulnerabilities to develop effective combination treatments. In this study, we demonstrate that vandetanib, a multi-kinase inhibitor, acts as a potent transcriptional repressor of the serine synthesis pathway (SSP) in...